Neurobiology of Aging
Volume 27, Issue 12 , Pages 1763-1768 , December 2006

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease

  • Daniela Galimberti

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 55033858; fax: +39 02 50320430.
    • ,
  • Chiara Fenoglio

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Carlo Lovati

      Affiliations

    • Department of Neurology, University of Milan, Ospedale L. Sacco, Milan, Italy
    • ,
  • Eliana Venturelli

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Ilaria Guidi

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Barbara Corrà

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Diego Scalabrini

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Francesca Clerici

      Affiliations

    • Department of Neurology, University of Milan, Ospedale L. Sacco, Milan, Italy
    • ,
  • Claudio Mariani

      Affiliations

    • Department of Neurology, University of Milan, Ospedale L. Sacco, Milan, Italy
    • ,
  • Nereo Bresolin

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy
    • ,
  • Elio Scarpini

      Affiliations

    • Department of Neurological Sciences, “Dino Ferrari” Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy

Received 17 June 2005 ,Revised 21 September 2005 ,Accepted 18 October 2005.

References 

  1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421
  2. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326
  3. Boehme SA, Lio FM, Maciejewski-Lenoir D, Bacon KB, Conlon PJ. The chemokine fractalkine inhibits Fas-mediated cell death in brain microglia. J Immunol. 2000;65:397–403
  4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  5. Dai C, Krantz SB. Interferon γ induces upregulation and activation of caspases 1, 3 and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93:3309–3316
  6. Del Bo R, Comi GP, Bresolin N, Castelli E, Conti E, Degiuli A, et al. The apolipoprotein E ɛ4 allele causes a faster decline of cognitive performances in Down's syndrome subjects. J Neurol Sci. 1997;145:87–91
  7. Fenoglio C, Galimberti D, Lovati C, Guidi I, Gatti A, Fogliarino S, et al. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging. 2004;25:1169–1173
  8. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, et al. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol. 1995;155:5769–5776
  9. Galimberti D, Schoonenboom N, Scarpini E, Scheltens P. On behalf of the Dutch-Italian Alzheimer Research Group. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann Neurol. 2003;53(4):547–548
  10. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YAL, et al. Intrathecal chemochine levels in Alzheimer's disease and Frontotemporal Lobar Degeneration. Neurology, in press.
  11. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, et al. In vivo properties of monocyte chemoattractant protein-1. J Leukocyte Biol. 1997;62:577–580
  12. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006;27:262–269
  13. Gunn MD, Nelken NA, Liao X, Williams LT. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol. 1997;158:376–383
  14. Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol. 2004;55(2):221–235
  15. Inadera H, Egashira K, Takemoto M, Ouchi Y, Matsushima K. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interf Cytokine Res. 1999;19:1179–1182
  16. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci. 1997;1:135–138
  17. Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res. 2004;297:197–211
  18. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med. 1998;187:601–608
  19. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–445
  20. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 1997;29:419–423
  21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  22. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001;58:397–405
  23. Morris TC. Mild cognitive impairment and preclinical Alzheimer's disease. Geriatrics. 2005;(Suppl 1):9–14
  24. Muessel MJ, Klein RM, Wilson AM, Berman NEJ. Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. Mol Brain Res. 2002;103:12–27
  25. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging. 1996;17(5):707–716
  26. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308
  27. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992
  28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Int Med. 2004;256:183–194
  29. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis. 1997;175:478–481
  30. Rollins BJ. Monocyte chemoattractanprotein-1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today. 1996;2:198–204
  31. Streit WJ. Microglia and macrophages in the developing CNS. Neurotoxicology. 2001;22:619–624
  32. Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2003;16:136–144
  33. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74:1200–1205
  34. Tarzami ST, Cheng R, Miao W, Kitsis RN, Berman TW. Chemokine expression inmyocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomvocvtes from cell death. J Mol Cell Cardiol. 2002;34:209–221
  35. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 Mrna in carrier males: a new mechanism of involvement in the Fragile-X Syndrome. Am J Hum Genet. 2000;66:6–15
  36. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002;23:485–508
  37. Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol. 2003;144:139–142
  38. Xia MQ, Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol. 1999;5:32–41

PII: S0197-4580(05)00336-2

doi: 10.1016/j.neurobiolaging.2005.10.007

Neurobiology of Aging
Volume 27, Issue 12 , Pages 1763-1768 , December 2006

Article Tools

* Image Usage & Resolution